Robert Owen Dillman

Summary

Affiliation: Hoag Cancer Center
Country: USA

Publications

  1. Dillman R, Duma C, Ellis R, Cornforth A, Schiltz P, Sharp S, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32:914-9 pubmed publisher
    ..Intralesional LAK cell therapy is safe and the survival sufficiently encouraging to warrant further evaluation in a randomized phase 2 trial of intralesional therapies with LAK or carmustine-impregnated wafers. ..
  2. request reprint
    Dillman R, Duma C, Schiltz P, DePriest C, Ellis R, Okamoto K, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27:398-404 pubmed
    ..The median survival rates are higher than reported in most published series of patients who underwent reoperation for recurrent GBM. A randomized trial would be needed to establish therapeutic benefit...

Detail Information

Publications2

  1. Dillman R, Duma C, Ellis R, Cornforth A, Schiltz P, Sharp S, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother. 2009;32:914-9 pubmed publisher
    ..Intralesional LAK cell therapy is safe and the survival sufficiently encouraging to warrant further evaluation in a randomized phase 2 trial of intralesional therapies with LAK or carmustine-impregnated wafers. ..
  2. request reprint
    Dillman R, Duma C, Schiltz P, DePriest C, Ellis R, Okamoto K, et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 2004;27:398-404 pubmed
    ..The median survival rates are higher than reported in most published series of patients who underwent reoperation for recurrent GBM. A randomized trial would be needed to establish therapeutic benefit...